Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Biropepimut-S - Gliknik

Next Previous
X
Search
Drug Profile

Biropepimut-S - Gliknik

Alternative Names: GL-0817; MAGE-A3 vaccine

Latest Information Update: 27 Sep 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mayo Clinic; University of Maryland, Baltimore
  • Developer Gliknik; University of Pennsylvania
  • Class Cancer vaccines; Peptides
  • Mechanism of Action Immunostimulants; MAGEA 3 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Head and neck cancer; Squamous cell cancer
  • No development reported Multiple myeloma

Most Recent Events

  • 27 Sep 2022 No development reported - Phase-II for Squamous cell cancer (Combination therapy, Second-line therapy or greater, Adjuvant therapy) in Germany (IV)
  • 27 Sep 2022 No development reported - Phase-II for Squamous cell cancer (Combination therapy, Second-line therapy or greater, Adjuvant therapy) in Russia (IV)
  • 27 Sep 2022 No development reported - Phase-II for Squamous cell cancer (Combination therapy, Second-line therapy or greater, Adjuvant therapy) in Serbia (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top